Comprehensive Network pharmacology and in vitro investigation of L-mimosine: unveiling multi-targeted therapeutic potential against breast cancer

Breast cancer remains the leading cause of mortality among women globally, primarily due to its heterogeneity and complex pathophysiology. Conventional treatments such as surgery, radiation therapy, and chemotherapy often face limitations, including significant side effects and the development of drug resistance. Consequently, there is an urgent need to identify novel, effective natural compounds with anti-tumor properties. L-mimosine, a non-protein amino acid derived from the seeds of Leucaena leucocephala and Mimosa pudica, has demonstrated cytotoxic activity against various cancers, including sarcoma, melanoma, breast cancer, and lung cancer. However, its precise molecular mechanisms remain poorly understood. To elucidate these mechanisms, a network pharmacology approach was employed, complemented by molecular docking, molecular dynamics simulations, and in vitro experiments to evaluate the impact of L-mimosine on breast cancer cell proliferation. Breast cancer-associated targets and L-mimosine-interacting genes were retrieved from multiple databases. Pharmacokinetic and toxicity properties were assessed through ADMET analysis. Protein-protein interaction networks of overlapping genes were constructed, identifying key hub genes such as SRC, MAPK8, PRKACA, and AKT1. Among these, AKT1 demonstrated the highest docking scores in molecular docking studies, and molecular simulations confirmed the stability of L-mimosine binding to AKT1. In vitro assays validated that L-mimosine inhibits breast cancer cell proliferation by inducing DNA damage and apoptosis in a dose-dependent manner. Furthermore, L-mimosine was found to arrest MCF-7 cells in the S phase of the cell cycle, as analyzed through cell cycle assays. This research highlights L-mimosine's potential as a promising anticancer agent against breast cancer by promoting apoptosis and interfering with cancer cell cycle progression.

Authors

Institutions

Publication Details

Journal
BMC Complementary Medicine and Therapies
Published
2025-09-01
DOI
https://doi.org/10.1186/s12906-025-04905-y
Citations
1
Primary Topic
Bioactive Compounds and Antitumor Agents
Type
article
Field-Weighted Citation Impact
1.31

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Comprehensive Network pharmacology and in vitro investigation of L-mimosine: unveiling multi-targeted therapeutic potential against breast cancer

Rakesh Rawal, Saumya Patel, Mohammadfesal Ghanchi, Krupa Shah et al.
1 citations
BMC Complementary Medicine and Therapies
Bioactive Compounds and Antitumor Agents
1.31
article

Comprehensive Network pharmacology and in vitro investigation of L-mimosine: unveiling multi-targeted therapeutic potential against breast cancer

Rakesh Rawal, Saumya Patel, Mohammadfesal Ghanchi, Krupa Shah, J. Yadav, Gaurang Sindhav
article en
1 citations

Abstract

Breast cancer remains the leading cause of mortality among women globally, primarily due to its heterogeneity and complex pathophysiology. Conventional treatments such as surgery, radiation therapy, and chemotherapy often face limitations, including significant side effects and the development of drug resistance. Consequently, there is an urgent need to identify novel, effective natural compounds with anti-tumor properties. L-mimosine, a non-protein amino acid derived from the seeds of Leucaena leucocephala and Mimosa pudica, has demonstrated cytotoxic activity against various cancers, including sarcoma, melanoma, breast cancer, and lung cancer. However, its precise molecular mechanisms remain poorly understood. To elucidate these mechanisms, a network pharmacology approach was employed, complemented by molecular docking, molecular dynamics simulations, and in vitro experiments to evaluate the impact of L-mimosine on breast cancer cell proliferation. Breast cancer-associated targets and L-mimosine-interacting genes were retrieved from multiple databases. Pharmacokinetic and toxicity properties were assessed through ADMET analysis. Protein-protein interaction networks of overlapping genes were constructed, identifying key hub genes such as SRC, MAPK8, PRKACA, and AKT1. Among these, AKT1 demonstrated the highest docking scores in molecular docking studies, and molecular simulations confirmed the stability of L-mimosine binding to AKT1. In vitro assays validated that L-mimosine inhibits breast cancer cell proliferation by inducing DNA damage and apoptosis in a dose-dependent manner. Furthermore, L-mimosine was found to arrest MCF-7 cells in the S phase of the cell cycle, as analyzed through cell cycle assays. This research highlights L-mimosine's potential as a promising anticancer agent against breast cancer by promoting apoptosis and interfering with cancer cell cycle progression.

BMC Complementary Medicine and TherapiesVol. 25(1)
Gujarat University (IN)
Department of Biotechnology, Ministry of Science and Technology, India, University Grants Commission
Openalex Percentile: Top 20%
Bioactive Compounds and Antitumor Agents
1.31
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.